Furniture Ros company information, Employees & Contact Information

ROS1 and Lung Cancer American Lung Association

Zidesamtinib Elicits Responses in ROS1-Positive NSCLC Cure Today

Zidesamtinib Demonstrates Responses in ROS1-Positive NSCLC After Prior TKI Treatment The ASCO Post

Ibtrozi Approved for Advanced ROS1 -Positive NSCLC Pulmonology Advisor

Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC Medical Xpress

Ibtrozi Emerging as New Standard for ROS1-Mutated Lung Cancer Cure Today

Zidesamtinib Shows Early Signs of Efficacy, Durability in Pretreated ROS1-Positive NSCLC Oncology News Central

ROS1-Directed Therapies Lead the Way in NSCLC Targeted Oncology

Ibtrozi May Address Unmet Needs In ROS1-Positive Non-Small Cell Lung Cancer Cure Today

Predicting ROS1 and ALK fusions in NSCLC from H&E slides with a two-step vision transformer approach Nature

Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC The American Journal of Managed Care® (AJMC®)

The 5-methylcytosine DNA glycosylase ROS1 prevents paternal genome hypermethylation in Arabidopsis endosperm Genome Biology

Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer The New England Journal of Medicine

Repotrectinib Shrinks ROS1-Positive NSCLC Tumors National Cancer Institute (.gov)

Positive lung cancer data sets up rolling FDA filing for Nuvalent's ROS1-targeted drug FirstWord Pharma

Selecting First-Line Therapy for ROS1 Fusion–Positive NSCLCs ASCO Daily News

Current Targeted Therapy Options in ROS1-Positive NSCLC Pharmacy Times

Progress of non-small-cell lung cancer with ROS1 rearrangement Frontiers

Novel insight into mechanisms of ROS1 catalytic activation via loss of the extracellular domain Nature

TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers Nature

FDA Approves Ibtrozi for ROS1-Positive Lung Cancer Cancer Health

ROS1 immunohistochemistry as a potential predictive biomarker for ROS1-targeted therapy in breast cancer: impact of antibody clone selection Wiley Online Library

Role of the Arabidopsis DNA glycosylase/lyase ROS1 in active DNA demethylation PNAS

The association of ROS1 mutation with cancer immunity and its impact on the efficacy of pan-cancer immunotherapy Journal of Translational Medicine

Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing BMC Cancer

FDA Approves Repotrectinib for ROS1 -Positive NSCLC Medscape

FDA Approves New Drug for Non-Small Cell Lung Cancer With ROS1 Fusions Memorial Sloan Kettering Cancer Center

Current treatment and novel insights regarding ROS1‐targeted therapy in malignant tumors Wiley Online Library

Entrectinib in ROS1 -positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial Nature

Direct identification of ALK and ROS1 fusions in non-small cell lung cancer from hematoxylin and eosin-stained slides using deep learning algorithms | Modern Pathology Nature

Exceptional response to lorlatinib and cabozantinib in ROS1-rearranged NSCLC with acquired F2004V and L2086F resistance | npj Precision Oncology Nature

Repotrectinib effective in ROS1-fusion-positive NSCLC Nature

ROS1-dependent cancers — biology, diagnostics and therapeutics Nature

Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition Nature

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models Nature

Crizotinib in ROS1 -Rearranged Non–Small-Cell Lung Cancer The New England Journal of Medicine

NICE shoots down Pfizer's Xalkori in ROS1-positive patients, inviting a CDF proposal instead Fierce Pharma

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials The Lancet

Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1 The New England Journal of Medicine

RET, ROS1 and ALK fusions in lung cancer Nature

Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers Nature